View Older Stories View More Recent Stories

Jan 16, 2024 07:30AM Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
Jan 8, 2024 07:39AM Anavex Life Sciences (AVXL) Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX 2-73) for Treatment of Neurodevelopmental Disorders
Jan 8, 2024 07:30AM Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders
Jan 3, 2024 07:30AM Anavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Jan 2, 2024 08:01AM Anavex Life Sciences (AVXL) Provides an Update on Rett Syndrome Program
Jan 2, 2024 08:00AM Anavex Life Sciences Provides an Update on Rett Syndrome Program
Dec 20, 2023 07:31AM Anavex Life Sciences (AVXL) Announces First Entire Clinical Gene Pathway Data of ANAVEX2-73 from AVATAR Study in Patients with Rett Syndrome
Dec 20, 2023 07:30AM Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Patients with Rett Syndrome
Dec 19, 2023 07:32AM Anavex Life Sciences (AVXL) Received Agreement from the CHMP for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer’s Disease
Dec 19, 2023 07:30AM Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer’s Disease
Nov 27, 2023 08:00AM Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update
Nov 24, 2023 08:00AM Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023
Nov 22, 2023 08:01AM Anavex Life Sciences (AVXL) Announces Grant of U.S. Patent for Blarcamesine
Nov 22, 2023 08:00AM Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Insomnia or Anxiety
Nov 20, 2023 08:00AM Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to European Medicines Agency (EMA)
Nov 6, 2023 08:00AM Anavex Life Sciences Appoints Senior VP of Regulatory Affairs
Oct 25, 2023 08:00AM Anavex Life Sciences Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX®3-71 to Prevent Cognitive Decline in Alzheimer’s Disease
Sep 14, 2023 07:30AM Anavex's (AVXL) Phase 2b/3 Trial of Blarcamesine Shows Robust Clinical Efficacy and Slows Neurodegeneration
Sep 14, 2023 07:30AM Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration
Sep 12, 2023 07:32AM Anavex Life Sciences (AVXL) Appoints Marwan N Sabbagh as Chair of Scientific Advisory Board
Sep 12, 2023 07:30AM Anavex Announces Appointment of Dr. Marwan N Sabbagh, MD as Chairman of the Scientific Advisory Board
Aug 8, 2023 07:30AM Anavex Life Sciences Reports Fiscal 2023 Third Quarter Financial Results
Aug 7, 2023 07:33AM Anavex Life Sciences (AVXL) Reports Publication of ANAVEX3-71 in Clinical Journal Confirming ANAVEX®3-71 Clinical Cardiovascular Safety
Aug 7, 2023 07:30AM Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming ANAVEX®3-71 Clinical Cardiovascular Safety
Aug 2, 2023 07:30AM Anavex Life Sciences to Present at the BTIG Virtual Biotechnology Conference 2023
Aug 1, 2023 07:30AM Anavex Life Sciences to Announce Fiscal 2023 Third Quarter Financial Results on Tuesday August 8, 2023
Jun 28, 2023 07:30AM Anavex Life Sciences (AVXL) Reports Study Showing Disease Modifying Effects of ANAVEX2-73 for Rett Syndrome
Jun 28, 2023 07:30AM Long-term Clinical Study Demonstrates Disease Modifying Effects of ANAVEX®2-73 (blarcamesine) for Rett Syndrome
Jun 27, 2023 07:30AM Anavex Life Sciences and Partex Group Announce Strategic Partnership to Leverage AI for Drug Development and Healthcare Sales Marketing Building a Patient-Centric Digital Ecosystem
Jun 20, 2023 07:30AM Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
Jun 15, 2023 07:31AM Anavex's (AVXL) blarcamesine Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome
Jun 15, 2023 07:30AM ANAVEX®2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome
Jun 12, 2023 07:30AM Anavex Life Sciences Reports Publication in Medical Journal Signifying Continued Commitment for Improvement of the Rett Syndrome Caregiver Outcome Measure RSBQ
Jun 6, 2023 07:30AM Anavex Life Sciences Announces Completion of ANAVEX(®)2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
Jun 1, 2023 07:30AM Anavex Life Sciences (AVXL) Announces Issuance of New U.S. Intellectual Property Compositions Patent for ANAVEX®2-73
Jun 1, 2023 07:30AM ANAVEX Announces Issuance of New U.S. Intellectual Property Compositions Patent for ANAVEX®2-73 (blarcamesine)
May 9, 2023 07:30AM Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results
May 2, 2023 07:30AM Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Results on Tuesday, May 9, 2023
May 1, 2023 07:31AM Anavex Life Sciences (AVXL) Announces Issuance of New U.S. Patent Expanding ANAVEX®2-73 (blarcamesine) Intellectual Property Portfolio for the Treatment of Hypertension
May 1, 2023 07:30AM Anavex Life Sciences Announces Issuance of New U.S. Patent Expanding ANAVEX®2-73 (blarcamesine) Intellectual Property Portfolio for the Treatment of Hypertension
Apr 25, 2023 07:30AM Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
Apr 10, 2023 07:00AM Anavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023
Mar 30, 2023 07:01AM Anavex Life (AVXL) Reports ANAVEX2-73 Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study
Mar 30, 2023 07:00AM ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson’s Disease Dementia
Mar 9, 2023 07:00AM Anavex Life Sciences Appoints Former FDA Lead Neurology Statistician as Vice President Head of Biostatistics
Feb 7, 2023 07:00AM Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results
Feb 2, 2023 07:00AM Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
Jan 31, 2023 07:00AM Anavex Life Sciences to Announce Fiscal 2023 First Quarter Financial Results on Tuesday February 7, 2023
Dec 14, 2022 07:00AM Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial
Dec 12, 2022 07:00AM Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
View More Recent Stories View Older Stories